About the Corporate Council

The ACAAI Corporate Council offers companies exposure to nearly 6,000 allergists and immunologists, including more than 3,000 who are board-certified by the ABAI.  Participation in the Corporate Council also provides valuable access to the ACAAI Board of Regents and other key opinion leaders.

The Corporate Council is comprised of senior executives from pharmaceutical, medical device and other companies involved in the field of allergy and immunology. Two representatives from each participating company will hold seats on the Corporate Council and will be invited to the annual Corporate Council roundtable meeting.

The Council’s goal is to address critical issues in allergy and immunology, find solutions to pressing challenges, share knowledge of best practices and advise members on upcoming initiatives. By pooling resources and expertise, Corporate Council members and the ACAAI leadership can engage in joint problem-solving and explore collaborative opportunities to improve patient care and advance the mission of ACAAI.

To learn more about becoming a member of the ACAAI Corporate Council, please contact:

Linda Cullison
Director of Corporate Relations
American College of Allergy, Asthma & Immunology
Phone: 847-725-2291
Email: lindacullison@acaai.org

2018 Corporate Council Partners

Aimmune Therapeutics, Inc.​
8000 Marina Blvd. Suite 200
Brisbane, CA 94005-1884

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is an oral biologic drug product with a characterized peanut protein profile for use in oral immunotherapy (OIT) in subjects with peanut allergy. For more information, please see www.aimmune.com.

ALK, Inc.​
1700 Royston Lane
Round Rock, Texas 78664
Tel: 512-251-0037
Fax: 512-251-5882
www.alk.net/us

As the World Leader in Allergy Immunotherapy (AIT), the only treatment that treats the underlying cause of allergic disease, ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop, and market new solutions beyond AIT, that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them will Allergy Specialists earlier in the disease progression.

AstraZeneca​
1800 Concord Pike
Wilmington, DE 19850
Tel: 800-236-9933
Tel: 877-810-6060
www.astrazeneca-us.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com.

Boston Scientific 
One Boston Scientific Way
Marlborough, MA 01752
Tel: 877-810-6060
www.btforasthma.com

Boston Scientific is committed to helping advance the diagnosis and treatment of pulmonary diseases by focusing on the development of less invasive devices and procedures. We have developed the first device to treat adult patients with severe asthma. Bronchial Thermoplasty (BT) delivered by the Alair™ System is a safe outpatient procedure clinically proven to provide long-lasting reduction in exacerbations. 79% of patients treated with BT had a significant improvement in their asthma-related quality of life.

Circassia Pharmaceuticals
1 DNA Way
5151 McCrimmon Parkway
Suite 260
Morrisville, NC 27560
www.circassia.com

Circassia is a specialty biopharmaceutical company focused on allergy and respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians, and we have a broad pipeline of allergy, asthma and COPD treatments in development.

DBV Technologies
25 DeForest Avenue, Suite 203
Summit, NJ 07901
www.dbv-technologies.com

DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV’s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.

Genentech
1 DNA Way
South San Francisco, CA 94080
www.gene.com

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

Kaleo
111 Virginia Street, Suite 300
Richmond, VA 23219

Kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions.

Optinose
1020 Stony Hill Road, Suite 300
Yardley, PA 19067
Tel: 267-364-3500
www.optinose.com

Optinose is a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat (ENT) and allergy specialists. Our mission is to improve the quality of life for patients. We will accomplish that by becoming the leading specialty pharmaceutical company dedicated to creating innovative products that become standard of care for diseases cared for directly by, or in consultation with, ENT and allergy specialists.

Pharming Healthcare, Inc.
685 Route 202/206, Suite 202
Bridgewater, NJ 08807
Tel: 800-930-5221
www.pharming.com

Pharming Healthcare, Inc. is dedicated to providing life-changing solutions to patients. Pharming is currently involved in the development of drugs for the treatment of hereditary angioedema and has marketing operations in the United States, Israel, all 28 European Union countries plus Norway, Iceland, and Liechtenstein.

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807
https://www.sanofi.us/en

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill Road
Tarrytown, NY 10591-6707
https://www.regeneron.com

Sanofi Genzyme and Regeneron are committed to providing resources to advance education and research in areas of unmet medical needs among patients with inflammatory and immunological diseases.

Teva Specialty
US Headquarters
Teva North America
1090 Horsham Road
North Wales, PA 19454
Tel: 888-TEVA-USA (888-838-2872)
www.tevausa.com

Teva Specialty is the U.S.-based respiratory subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a leading global pharmaceutical company and the world's largest generic drug maker. Teva has a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. The company is committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.